Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444574 | 1.00 | LMNA (0.43) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL1979948 | 1.00 | LMNA (0.43) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL19884578 | 0.93 | LMNA (0.39) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL17802928 | 0.91 | PDE4A (0.40) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL13083485 | 0.88 | PLG (0.35) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL19431411 | 0.88 | PLG (0.35) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL19431353 | 0.88 | PLG (0.35) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL19431412 | 0.88 | PLG (0.35) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL19431525 | 0.88 | PLG (0.35) | LMNAPLGPLATGABRPGABRD | |
| SCHEMBL19431355 | 0.88 | PLG (0.35) | LMNAPLGPLATGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| EP-1618090-A1 | 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-01-25 | — | — | EP | claimed |
| US-20050272132-A1 | Production of polyketides and other natural products | BIOTICA TECHNOLOGY LIMITED (GB) | 2005-12-08 | — | — | US | claimed |
| EP-1589031-A2 | Production of polyketides and other natural products | Biotica Technology Limited (GB) | 2005-10-26 | — | — | EP | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| WO-2004089896-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| EP-0962459-B1 | DIACETAL COMPOSITION, PROCESS FOR THE PREPARATION OF THE SAME, NUCLEATING AGENT FOR POLYOLEFINS CONTAINING THE SAME, POLYOLEFIN RESIN COMPOSITIONS, AND MOLDINGS | NEW JAPAN CHEM CO LTD (JP) | 2003-10-01 | — | — | EP | claimed |
| US-20020028864-A1 | Diacetal composition, process for preparing the same, polyolefin nucleating agent containing said composition, polyolefin resing compositions and molded articles | KOBAYASHI TOSHIAKI (JP) | 2002-03-07 | — | — | US | claimed |
| US-6245843-B1 | POWDER IN BINDER | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2001-06-12 | — | — | US | claimed |
| EP-0962459-A1 | DIACETAL COMPOSITION, PROCESS FOR THE PREPARATION OF THE SAME, NUCLEATING AGENT FOR POLYOLEFINS CONTAINING THE SAME, POLYOLEFIN RESIN COMPOSITIONS, AND MOLDINGS | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1999-12-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | LMNA 3959/4885PLG 4259/4885PLAT 1470/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | LMNA 2106/4885PLG 213/4885PLAT 160/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | LMNA 2024/4885PLG 4074/4885PLAT 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.